Literature DB >> 23674259

Characterization of the inhibitor of kappaB kinase (IKK) complex in granulosa cell tumors of the ovary and granulosa cell tumor-derived cell lines.

Stacey Jamieson1, Peter J Fuller.   

Abstract

Granulosa cell tumors of the ovary (GCT) are a distinct, hormonally active subset of ovarian cancers. Although it has recently been shown that ∼97 % of all adult GCT harbor a novel somatic missense mutation in the FOXL2 gene, given its almost universal presence, it does not explain differences in tumor stage and/or recurrence. The nuclear factor kappaB (NFκB) transcription factor is constitutively active in two human GCT-derived cell lines, COV434 and KGN, which are useful in vitro models to investigate juvenile and adult GCT, respectively. This study aimed to determine the molecular basis and pathogenetic significance of this aberrant NFκB activity. Selective chemical inhibitors were used to target candidate components of the pathway. The constitutive activity was blocked by two independent inhibitors of IκBα phosphorylation, suggesting that aberrant activation occurs upstream of this point. NFκB inhibition resulted in a dose-dependent decrease in cell proliferation and viability and a dose-dependent increase in apoptosis. Inhibitors of earlier components of the pathway were without effect. Two independent inhibitors of inhibitor of kappaB kinase (IKK)β, a catalytic subunit of the NFκB activation complex, were unable to inhibit the constitutive activity, but surprisingly also ligand-induced activity. These findings suggest a central role for IKKβ; however, no mutations or altered expression of the IKKβ, IKKα, or IKKγ genes was observed in the cell lines or in a panel of human GCT samples. This study highlights unresolved issues in understanding the pathogenesis of GCT and in the use of the COV434 and KGN cells lines as model systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23674259     DOI: 10.1007/s12672-013-0146-x

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  61 in total

1.  Novel IKK inhibitors: beta-carbolines.

Authors:  Alfredo C Castro; Luan C Dang; François Soucy; Louis Grenier; Hormoz Mazdiyasni; Maria Hottelet; Lana Parent; Christine Pien; Vito Palombella; Julian Adams
Journal:  Bioorg Med Chem Lett       Date:  2003-07-21       Impact factor: 2.823

2.  FOXL2 mutation in granulosa-cell tumours of the ovary.

Authors:  Taeeun Kim; Chang Ohk Sung; Sang Yong Song; Duk-Soo Bae; Yoon-La Choi
Journal:  Histopathology       Date:  2010-02       Impact factor: 5.087

Review 3.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

4.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

5.  Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.

Authors:  Q Li; D Van Antwerp; F Mercurio; K F Lee; I M Verma
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

6.  No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors.

Authors:  P J Fuller; K Verity; Y Shen; P Mamers; T Jobling; H G Burger
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

7.  Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers.

Authors:  Min Sung Kim; Soo Young Hur; Nam Jin Yoo; Sug Hyung Lee
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

8.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.

Authors:  M A Kelliher; S Grimm; Y Ishida; F Kuo; B Z Stanger; P Leder
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

9.  Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers.

Authors:  R L Stouffer; M S Grodin; J R Davis; E A Surwit
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

10.  The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.

Authors:  Kasmintan A Schrader; Bella Gorbatcheva; Janine Senz; Alireza Heravi-Moussavi; Nataliya Melnyk; Clara Salamanca; Sarah Maines-Bandiera; Susanna L Cooke; Peter Leung; James D Brenton; C Blake Gilks; John Monahan; David G Huntsman
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more
  5 in total

Review 1.  Adult-type granulosa cell tumor of the ovary.

Authors:  Xiuwen Li; Bo Tian; Mengyan Liu; Chunlei Miao; Di Wang
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  FOXL2C134W-Induced CYP19 Expression via Cooperation With SMAD3 in HGrC1 Cells.

Authors:  Martina Belli; Nahoko Iwata; Tomoko Nakamura; Akira Iwase; Dwayne Stupack; Shunichi Shimasaki
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

3.  Transcriptomic analysis of stage 1 versus advanced adult granulosa cell tumors.

Authors:  Maria Alexiadis; Simon Chu; Dilys Leung; Jodee A Gould; Tom Jobling; Peter J Fuller
Journal:  Oncotarget       Date:  2016-03-22

Review 4.  NF-κB Signaling in Ovarian Cancer.

Authors:  Brittney S Harrington; Christina M Annunziata
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

Review 5.  Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.

Authors:  Andrew Paul; Joanne Edwards; Christopher Pepper; Simon Mackay
Journal:  Cells       Date:  2018-10-20       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.